C A R D I A C FA I L U R E R E V I E W
Potential definitions of FS are often synonymous with disability, multimorbidity or advanced old age. 1, 11 In geriatric medicine, FS is characterised as a biological syndrome associated with decreased reserves and resistance to stressors, resulting from an accumulation of deficits in multiple physiological systems, and causing vulnerability to adverse outcomes. FS is also likely to be associated with impairment of physiological processes or reserves in other systems, leading to a reduced capacity to maintain homeostasis when stressors are present, causing weaknesses. 1, 2, 11, 12 Nonetheless, 30% of the normal physiological reserves is considered a level sufficient to maintain adequate function of basic organs. 13 With regard to homeostatic reserve decrease, three stages of frailty can be described: the initial process, the state of frailty and frailtyrelated complications.
The initial process is clinically silent. In this state, sufficient physiological reserves are maintained, the body reacts adequately to changes -such as acute disease, trauma or stress -and full recovery is possible.
The state of frailty can easily be diagnosed clinically. It includes slow and incomplete recovery after each subsequent incidence of acute disease, trauma or stress, which indicates that available reserves are insufficient for full recovery.
Progression of FS is associated with a high risk of frailty-associated complications, including falls, functional deficits leading to disability, polypharmacy, hospitalisation, cross-infection, institutionalisation and mortality. 2, 13 FS corresponds to an intermediate period between unimpaired psychophysical functioning with full recovery capacity and a state of disability with impaired ability to recover.
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Frailty Syndrome Pathophysiology
Most available scientific reports agree that FS involves increased vulnerability to biological stressors and its diagnosis should be based on an assessment of five criteria: slowness, weakness, physical activity, exhaustion and muscle mass. 14 Unfortunately, it is often not easy to make a distinction between the clinical symptoms and signs related to ageing, chronic illness or frailty. It is even unclear whether frailty is an independent syndrome or a result of chronic illness or developing multiple comorbidities with ageing. 15 Some authors show that frailty syndrome can be diagnosed in people who do not demonstrate any chronic illness. 1 Others argue that chronic illnesses and frailty share many characteristics, the most commonly cited example being heart failure (HF). Therefore, there is a link between FS and HF. HF is becoming a major challenge in cardiology, primarily owing to the rising prevalence because of ageing populations in developed countries. According to current estimates, by 2050, more than 40% of the population of western Europe will be 60 or older. 16 A similar trend applies in Poland, where people aged 60 and above are expected to account for 35% of the population by the middle of this century. 17 The incidence of FS increases with age, so the number of patients with concurrent FS and HF is anticipated to rise. Frailty is considered one of the most important issues associated with human ageing, and this has significant implications for patients and the healthcare system. 1 The relationship between frailty and a higher risk of falling, loss of functional independence, reduced quality of life, institutionalisation
and mortality has been clearly demonstrated. 18, 19 Both frail patients and those with HF may demonstrate poor tolerance of exertion, exhaustion and loss of body weight (muscle mass).
Distinguishing frailty syndrome from heart failure may be particularly difficult in the elderly, who tend to show HF with preserved ejection fraction. 14 Up to 25% of elderly patients with heart failure show frailty, and frail patients have an increased risk of developing heart failure. [20] [21] [22] Frailty in chronic HF has been reported as possibly reversible in a study of patients undergoing heart transplantation or implantation of ventricular assist devices. 23 There seems to be a clear relationship between HF, ageing and frailty;
however, this is poorly understood. All of the above-mentioned conditions are associated with elevated inflammatory markers, so a common inflammatory background has been proposed. 15 This can be attributed to several mechanisms. A model of sterile inflammation has been proposed, where the breakdown of tissue (sterile cell necrosis without microbial invasion) connected with conditions such as ageing, MI and HF frees cellular substances, which in turn provokes a degree of immune response. 24 Such a mechanism seems to explain some of the common features of HF, ageing and frailty, because most of the signs and symptoms common in these conditions can be attributed to sarcopenia (loss of muscle mass). In this model, degradation of muscular tissue causes chronic, sterile inflammation. Quality of life (QoL) is low in both the HF and the frail populations.
Multimorbidity and physical, psychological and social frailty problems have been demonstrated to correlate negatively with QoL. [25] [26] [27] It is generally accepted that almost half of the total population in Europe has at least one long-term condition. Among the most common chronic conditions in the European population are arthritis, diabetes, heart disease, cancer and stroke. 28 Many patients have two or more concurrent chronic diseases, especially those aged 65 years or older. Multimorbidity is associated with hospitalisation, emergency department visits and a reduction in QoL. 12, 13 It is more common in women than men.
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Frailty Syndrome Epidemiology
Both frailty and HF are common in the elderly population. It is estimated that HF affects at least 26 million people worldwide. 29 The incidence of HF is associated with age -at 65 years, the estimated incidence of HF is 1% and this percentage approximately doubles with each decade of age thereafter. 30 Moreover, people aged 65 years or older constitute more than 80% of those with HF, and 25% of these patients are aged 80 years or older. In community-dwelling older people aged 65 years or older, the prevalence of frailty varies enormously, and has been found to range from 4.0% to 59.1%. 35 Currently, no frailty instrument has been validated specifically for people with HF. 36 The most commonly used instrument is the phenotype of frailty, followed by the Comprehensive Geriatric Assessment and the FI. 1, 32, 33 The use of these different instruments in people with HF explains why the prevalence figures of frailty in this target group also differ.
Denfeld et al. conducted a systematic review and meta-analysis that aimed to quantitatively synthesise studies about the prevalence of frailty in people with HF. 37 The overall prevalence of frailty in people with HF was found to be 44.5%. The authors also demonstrated that the prevalence of frailty was lower in studies using physical frailty than in those that also included psychological and/or social components of frailty, also called multidimensional frailty (42.9% versus 47.4%).
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Many studies have shown that frailty is associated with older age. 40 Moreover, the prevalence of frailty was higher among women than among men (62.6% versus 33.7%). These findings were supported by Lupón et al. 41 From the prevalence figures, it can be deduced that frailty and HF are closely linked. This is also evident from the results of two studies. 22, 42 The Longitudinal Aging Study Amsterdam (LASA) revealed that community-dwelling elderly people with HF had an increased risk of frailty, independent of potential confounders such as sex, age and multimorbidity. 42 The Health ABC Study, which had a follow-up of 11.4 years and included 2,825 people with a mean age of 74 years at baseline, demonstrated that frailty is independently associated with risk of HF in older people. 22 Frailty is common in people with HF because the pathophysiology of HF contributes to frailty by reducing both skeletal muscle function and exercise capacity. 43 Frailty and HF are probably the result of similar pathways involving inflammatory processes as well as metabolic and autonomic disturbances. 44 In addition, the development of frailty in people with HF may be accelerated because they are more susceptible to falls and are more likely to have cognitive impairment because of reduced cerebral perfusion. 43 More major longitudinal studies are necessary to create clarity regarding the cause and effect relationship between frailty and HF.
Assessment Instruments for Frailty Syndrome
FS, rather than chronological age, is considered a significant risk factor for cardiovascular disease, and a significant predictor of outcomes.
One important issue related to identifying frail patients is distinguishing between multimorbidity and/or disability and concurrent FS. Early FS identification offers an opportunity to provide individualised, targeted healthcare. Prevention of complications is a strategic health-related issue and should be prioritised in the process of evidence-based therapeutic decision-making in elderly patients. Identification of frailty or early identification of pre-frailty may be significant in the prevention of FS consequences. FS diagnosis remains a challenge. Health and social care professionals have to choose the most suitable assessment instrument. 45 These are outlined below.
Edmonton Frail Scale
The Edmonton Frail Scale (EFS) comprises 10 domains evaluating cognitive function, balance, mobility, mood, independent daily functioning, medication, eating, health attitudes, social support and QoL. It should take less than 15 minutes to administer. The 'clock test' is used to assess cognitive function, and a walking test to evaluate balance and mobility. The maximum score is 17; scores of 0-3 indicate no frailty, and scores above 9 indicate the highest level of frailty. 46 
Cardiovascular Health Study Scale
The Cardiovascular Health Study Scale (CHS) is one of the most commonly used frailty scales, and assesses its most important criteria. 1 These include:
• unintentional weight loss (>5 kg in 12 months);
• decreased grip strength, as measured using a dynamometer, taking the patient's age and body mass index (BMI) into consideration;
• exhaustion, as measured using a depression scale (CES-D, Center 
Tilburg Frailty Indicator
The TFI was developed by Gobbens et al. 34 Part A covers health-related determinants of frailty, while part B comprises 15 questions regarding the main FS components. The TFI includes three subscales, with eight physical, four psychological and three social components. There are no criteria for identifying high or low scores on each subscale, so results must be interpreted by comparing a patient's score with the maximum for each subscale. Moreover, each subscale includes a different number of questions, which also affects the interpretation.
The maximum score for the entire scale is 15 points. Frailty is identified when a patient scores 5 or more. The questionnaire covers deficits that interfere with daily functioning in elderly individuals, including:
• alarming symptoms: sleep disorders, memory impairment, low mood;
• physical signs, such as tremors and weakened pulse;
• laboratory results, including in particular abnormal creatinine and calcium levels;
• comorbidities, e.g. diabetes or Parkinson's disease;
• disability components, including limitations in activities of daily living such as washing, dressing, using the toilet and eating.
Depending on the results, each patient is categorised as: very fit, fit, managing well, vulnerable, mildly frail, moderately frail or severely frail.
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FRAIL Scale
The FRAIL scale is a simple instrument recommended by the 
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Prognostic Role of Frailty in Heart Failure
The clinical consequences of concurrent frailty in patients with HF can vary, depending on the severity of both FS and HF. FS is often associated with limiting physical activity to the basic activities of daily living, such as washing or dressing, which may mask HF symptoms, as the latter are typically exacerbated by effort. and social. The focus should on characteristics such as poor physical
health, a lack of social relations, a lack of social support, feeling down and being unable to cope with problems, as these issues -as well as frailty components and HF -have the biggest impact on QoL in the elderly.
74
Directions for Future Research
It is well known that frailty has many adverse outcomes in the general population of older people, including disability, institutionalisation, hospitalisation, lower QoL and premature death. 1, 52, 76, 77 Logically, frailty also has several negative consequences for people with heart failure.
A recent systematic review and meta-analysis based on 20 studies
showed that frailty, measured with a wide variety of scales (e.g. the phenotype of frailty by Fried et al., FI, Canadian Study of Health and
Aging Clinical Frailty Scale) is a significant predictor of all-cause mortality and hospital readmissions in people with heart failure. 1, 33, 52, 78 In addition, in people with advanced HF, the risk of all-cause mortality after undergoing a ventricular assist device (VAD) implantation was significantly higher in those with frailty than in non-frail people. Moayedi et al. showed that, adjusted for B-type natriuretic peptide or peak oxygen consumption (VO 2 ), frailty identified using the phenotype of frailty was not associated with increased mortality in people with advanced HF. 80 However, Moayedi et al. also found that when peak VO 2 was stratified into two categories (≥12 ml/kg/min versus <12 ml/kg/min), frailty was associated with a 72% higher risk of death in this group. 80 Of the individual phenotype of frailty components, low physical activity assessed with the Duke Activity Status Index was associated with the highest risk of death. 81 and neurovascular -were associated with differences in the length of stay, the risk of death and cost. 93 Together with frailty profiles, these comorbidity profiles could be helpful in identifying people with HF who are at a high risk of adverse outcomes while in hospital.
Despite the poor prognosis of people with both HF and frailty, it is important to note that frailty can be reversed or improved in people Old age is a significant predictor of FS. Other determinants of FS include strength, mobility, energy/fatigue, physical activity, nutrition, polypharmacy and cognitive function.
Elderly HF patients are at a higher risk of developing FS, but a converse relationship also exists in that patients aged above 65 years with multimorbidity are at a higher risk of developing HF. 97 Thus, FS and HF have a bidirectional association, believed to be caused by proinflammatory factor activation, metabolic dysfunction and hormone dysregulation. Moreover, FS symptoms are found in nearly half of all patients with HF. 98 A variety of unidimensional and multidimensional instruments are used in FS diagnosis. 99 Regardless of the model used, a diagnosis of FS is associated with adverse outcomes. 82, 85, 97, [100] [101] [102] Consequences of concurrent FS in HF patients include an increase in hospital admission, poorer prognosis, higher risk of disability and falls, cognitive impairment and decreased QoL. In addition, increased severity of FS symptoms is associated with a fourfold increase of rehospitalisation risk and an increase in 1-year mortality in HF patients. 100 Considering FS and its implications may be a decisive factor in the diagnosis and treatment process for patients with HF. 22, 103 For multidisciplinary healthcare teams, managing frail patients with HF remains a challenge. The overall objective of any intervention should be to improve outcomes, decrease hospitalisation, improve
QoL and provide continued care. 104 
Clinical Implications
Accurate evaluation in patients with FS and HF allows for the implementation of an individualised healthcare programme to prevent the adverse consequences of FS. Therefore, a consistent, multidimensional evaluation is necessary. Multidisciplinary teams should focus on rapid diagnosis to identify the high-risk group of patients with HF and concurrent FS, as this may be a decisive factor in improving prognosis and QoL in these patients.
HF treatment remains a challenge, especially in patients with concurrent FS. Providing comprehensive specialist care to patients with HF and FS should be a priority, and diagnosis and treatment optimised.
Implementation of strategies for identifying FS in patients with HF may be decisive with regard to individualisation of treatment and care plans.
There is an urgent need for accurate risk estimation, including factors associated with FS, in patients with HF. Management of HF should include the implementation of interventions to prevent frailty, alleviate its symptoms and prevent or limit its consequences. This objective may be achieved only through skilful collaboration between all team members, with a multidimensional consideration of frail HF patients. n
